Research programme: oral film benign prostatic hyperplasia therapeutics - IntelGenxAlternative Names: INT0025; INT0025/2010; INT0026; INT0026/2011
Latest Information Update: 23 Dec 2013
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 12 Dec 2013 No development reported - Preclinical for Benign prostatic hyperplasia in Canada (PO)